BML, Inc. (TYO:4694)

Market Cap	152.75B +41.7%
Revenue (ttm)	149.09B +5.5%
Net Income	7.56B +24.3%
EPS	196.62 +26.1%
Shares Out	37.48M
PE Ratio	20.72
Forward PE	20.71
Dividend	120.00 (2.91%)
Ex-Dividend Date	Mar 30, 2026

Volume	42,700
Average Volume	55,960
Open	4,165.00
Previous Close	4,125.00
Day's Range	4,035.00 - 4,165.00
52-Week Range	2,663.00 - 4,175.00
Beta	0.22
RSI	62.77
Earnings Date	Feb 6, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1955
• Employees: 4,558
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4694

Financial Performance

In fiscal year 2025, BML, Inc.'s revenue was 143.19 billion, an increase of 3.79% compared to the previous year's 137.96 billion. Earnings were 6.26 billion, an increase of 3.80%.